Business Context and Reporting Period
This Form 8-K is filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on August 9, 2018. The filing serves to announce the company's financial results for the second quarter ended June 30, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the correct registrant name is Cerecor Inc., as the input metadata incorrectly listed Avalo Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual Q2 2018 financial figures, as they are absent from the 8-K text.
- Confirm the company's status as an Emerging Growth Company and its election to use the extended transition period for accounting standards.
- Note that the financial data in this filing is not subject to Section 18 liabilities of the Exchange Act.